Margaret K. Yu

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N., Neeraj Agarwal, Anders Bjartell et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan, Matthew R. Smith, Karim Fizazi et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Oncology, Urology +17

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono et al. · European Urology · 2014 · 273 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

Fred Saad, David Cella, Ethan Basch et al. · The Lancet Oncology · 2018 · 128 citations

Medicine, Oncology, Pharmacology +12